Mylan Pares Losses as Path to Generic Advair Approval Smoothed
- Shares reversed after hit from second-quarter earnings miss
- Earnings forecast for 2018 cut for the first time since 2012
1498148040_drugs-pharma
This article is for subscribers only.
Mylan shares briefly pulled out of an early-morning swoon after executives tempered concern about regulatory roadblocks for some of its new drugs.
Approval of a highly anticipated generic version of the asthma treatment Advair, which was delayed, won’t require additional clinical or device approvals, Mylan President Rajiv Malik said on a conference call. That helped placate investors who had driven Mylan down as much as 7 percent early Wednesday after the company cut its forecast for this year and the next. The shares rose as much as 2.8 percent during the call and were down 2 percent to $31.16 at 12:05 p.m. in New York.